Holen Sie sich die Stockscreener-App
12.29
3.98%
-0.51
Vorhandelsmarkt:
12.47
0.18
+1.46%
Schlusskurs vom Vortag:
$12.80
Offen:
$14.49
24-Stunden-Volumen:
4.79M
Relative Volume:
1.27
Marktkapitalisierung:
$1.37B
Einnahmen:
$631.73M
Nettoeinkommen (Verlust:
$-239.78M
KGV:
-6.0842
EPS:
-2.02
Netto-Cashflow:
$-33.45M
1W Leistung:
-6.04%
1M Leistung:
+0.33%
6M Leistung:
-13.75%
1J Leistung:
-37.14%
1-Tages-Spanne:
$11.88
$14.49
1-Wochen-Bereich:
$11.88
$14.49
52-Wochen-Spanne:
$6.78
$24.76
10 X Genomics Inc Stock (TXG) Company Profile
Firmenname
10 X Genomics Inc
Sektor
Branche
Telefon
(925) 401-7300
Adresse
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Vergleichen Sie TXG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
12.29 | 1.56B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
282.13 | 46.19B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
60.87 | 9.61B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
66.58 | 10.89B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
93.05 | 7.86B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
34.59 | 5.92B | 906.14M | -52.62M | 89.62M | -0.3621 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-07-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-05-01 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-10 | Eingeleitet | Barclays | Overweight |
| 2023-03-31 | Eingeleitet | Stephens | Overweight |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-08-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-07-25 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-07-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-14 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-15 | Eingeleitet | William Blair | Outperform |
| 2020-12-02 | Eingeleitet | Goldman | Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-10 | Eingeleitet | Stifel | Buy |
| 2020-03-05 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-07 | Eingeleitet | BofA/Merrill | Buy |
| 2019-10-07 | Eingeleitet | Cowen | Outperform |
| 2019-10-07 | Eingeleitet | JP Morgan | Overweight |
| 2019-09-24 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
10 X Genomics Inc Aktie (TXG) Neueste Nachrichten
10x Genomics to Acquire Scale Biosciences - FinSMEs
Why 10x Genomics (TXG) Is Down 6.0% After Tariff-Driven Q2 Revenue Surge and Guidance Update - simplywall.st
Why 10x Genomics (TXG) Stock Is Falling Today - FinancialContent
10x Genomics, Inc. SEC 10-Q Report - TradingView
10x Genomics (NASDAQ:TXG) Reports Upbeat Q2, Stock Soars - Yahoo Finance
10x Genomics Inc (TXG) Q2 2025 Earnings Call Highlights: Navigating Revenue Shifts and ... By GuruFocus - Investing.com Canada
10x Genomics Inc (TXG) Q2 2025 Earnings Call Highlights: Navigat - GuruFocus
10x Genomics Invests in the Future with Scale Biosciences Acquisition, Eyes Scalable Growth - geneonline.com
10X Genomics Outpaces Estimates And Returns To Profit - Finimize
10x Genomics (TXG) Reports Q2 Earnings: What Key Metrics Have to Say - Yahoo Finance
10x Genomics (TXG) Surpasses Q2 Earnings and Revenue Estimates - Yahoo Finance
10X Genomics' Q2 revenue beats estimates - MarketScreener
10x Genomics: Q2 Earnings Snapshot - San Francisco Chronicle
10x Genomics to acquire Scale Biosciences to expand single cell analysis - Investing.com
Earnings Flash (TXG) 10x Genomics, Inc. Reports Q2 Revenue $172.9M, vs. FactSet Est of $139.4M - MarketScreener
(TXG) 10x Genomics, Inc. Expects Q3 Revenue Range $140.0M$144.0M - MarketScreener
10x Genomics Reports Second Quarter 2025 Financial Results – Company Announcement - Financial Times
Transcript : 10x Genomics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Earnings To Watch: 10x Genomics (TXG) Reports Q2 Results Tomorrow - Yahoo Finance
10x Genomics Inc. Recovery Potential Based on Technical ToolsScalable Portfolio Growth Suggestions Released - metal.it
Is 10x Genomics Inc. a growth stock or a value stockHigh-octane investment opportunities await - Jammu Links News
What is the dividend policy of 10x Genomics Inc. stockOverwhelming profit margins - Jammu Links News
What are analysts’ price targets for 10x Genomics Inc. in the next 12 monthsFree Predictions - Jammu Links News
Is 10x Genomics Inc. stock overvalued or undervaluedDynamic profit opportunities - Jammu Links News
What catalysts could drive 10x Genomics Inc. stock higher in 2025Remarkably fast returns - Jammu Links News
What are 10x Genomics Inc. company’s key revenue driversAchieve breakthrough performance with smart picks - Jammu Links News
What is the risk reward ratio of investing in 10x Genomics Inc. stockBuild wealth with steady, reliable stocks - Jammu Links News
What institutional investors are buying 10x Genomics Inc. stockRobust investment performance - Jammu Links News
10x Genomics' (TXG) "Sell (E+)" Rating Reiterated at Weiss Ratings - MarketBeat
When is 10x Genomics Inc. stock expected to show significant growthDaily Trading Signals That Work - Jammu Links News
Options Data Show Bullish Bias in 10x Genomics Inc.Smart Money Tracking Signal Generator Activated - metal.it
Building trade automation scripts for 10x Genomics Inc.Low Risk Picks for Daily Trading Released - metal.it
10x Genomics Inc. Recovery Likely Here’s What Data ShowsFree Signals Group - beatles.ru
10x Genomics Inc. Price Targets Raised After ReboundWeekly Setup With 3x Return Potential Published - metal.it
10x Genomics Inc. Stock Lags Behind Sector BenchmarksInvestment Plan With Growth Optimization Finalized - beatles.ru
PacBio, 10x Genomics, QuidelOrtho, STAAR Surgical, and Clover Health Stocks Trade Down, What You Need To Know - TradingView
Why 10x Genomics Inc. stock attracts strong analyst attentionReliable Investment Entry Signals Confirmed by Charts - beatles.ru
RSI and MACD Indicate Shift in 10x Genomics Inc. SentimentEntry Alert Based on Volume Spikes Detected - metal.it
AI Trend Models Suggest Bounce for 10x Genomics Inc.Market Entry and Exit Point Tips From Traders - metal.it
Is 10x Genomics Inc. Starting a New UptrendWealth Building Stock Market Ideas Based on Momentum - beatles.ru
Is it the right time to buy 10x Genomics Inc. stockNavigate the market with precision tools - jammulinksnews.com
Short Covering May Lift 10x Genomics Inc. in Near TermSafe Entry Stock Watch Suggestions for Cautious Traders - metal.it
How volatile is 10x Genomics Inc. stock compared to the marketValue Investing Tracker To Watch Now - jammulinksnews.com
What is 10x Genomics Inc. company’s growth strategyTrack stocks with high upside potential easily - jammulinksnews.com
Why 10x Genomics Inc. stock attracts strong analyst attention Technical Screener for High Growth Stocks - metal.it
10x Genomics (TXG): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Finanzdaten der 10 X Genomics Inc-Aktie (TXG)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.97%
6.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):